🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/04/2020 135,00 136,30 132,90 136,20 +1,41% 2,52% 56.239
17/04/2020 133,40 135,30 132,50 134,30 +3,47% 2,10% 95.485
16/04/2020 126,50 133,40 124,70 129,80 +2,61% 6,88% 100.693
15/04/2020 129,00 130,70 125,20 126,50 -2,47% 4,26% 80.402
14/04/2020 131,20 135,00 129,00 129,70 -0,08% 4,57% 114.078
09/04/2020 131,00 134,40 127,60 129,80 -0,92% 5,19% 73.532
08/04/2020 128,50 131,50 126,00 131,00 +0,15% 4,28% 46.038
07/04/2020 130,20 133,30 127,50 130,80 +2,19% 4,45% 72.425
06/04/2020 126,70 130,00 126,20 128,00 +4,40% 3,00% 85.499
03/04/2020 122,00 123,00 119,80 122,60 +0,57% 2,62% 35.184
02/04/2020 120,00 121,90 116,90 121,90 +1,58% 4,17% 41.449
01/04/2020 121,50 121,50 116,50 120,00 -2,44% 4,12% 65.075
31/03/2020 121,50 124,80 120,30 123,00 +2,59% 3,70% 80.312
30/03/2020 118,50 121,50 116,20 119,90 +0,93% 4,47% 49.585
27/03/2020 118,50 122,10 115,20 118,80 -1,00% 5,82% 73.863
26/03/2020 118,00 120,50 114,10 120,00 +0,42% 5,42% 71.743
25/03/2020 127,00 132,90 118,80 119,50 -2,92% 11,10% 120.403
24/03/2020 122,30 124,50 119,80 123,10 +7,79% 3,84% 112.037
23/03/2020 112,20 116,40 110,30 114,20 -3,63% 5,44% 75.110
20/03/2020 122,50 124,10 116,60 118,50 +2,51% 6,12% 151.671
19/03/2020 109,50 118,10 108,60 115,60 +6,54% 8,68% 180.706
18/03/2020 104,00 109,10 102,00 108,50 +4,53% 6,83% 118.444
17/03/2020 107,40 109,80 98,00 103,80 +1,76% 10,99% 133.056
16/03/2020 100,00 104,50 93,05 102,00 -0,97% 11,45% 225.693
13/03/2020 107,00 116,50 100,70 103,00 -3,29% 14,77% 223.415
12/03/2020 112,40 114,30 102,00 106,50 -11,40% 10,94% 271.443
11/03/2020 126,30 128,40 118,60 120,20 -3,14% 7,76% 218.144
10/03/2020 127,10 133,50 123,20 124,10 -1,19% 8,10% 232.171
09/03/2020 126,00 129,20 123,00 125,60 -7,17% 4,92% 240.379
06/03/2020 133,40 136,20 130,80 135,30 -1,24% 4,05% 193.248